参考文献：
[1] Alas, M., et al. Peptide−Drug Conjugates with Different Linkers for Cancer Therapy. J. Med. Chem. 2021, 64, 216.
[2] Su, Z., et al. Antibodye-drug conjugates: Recent advances in linker chemistry. Acta Pharmaceutica Sinica B, 2021, 11, 3889.
[3] Hamann, P. R. et al. Bioconjugate Chem., 2002, 13, 47.
[4] Bargh, J. D., et al. Cleavable linkers in antibody–drug conjugates, Chem. Soc. Rev. 2019, 48, 4361.
[5] Pillow, T. H. et al. Mol. Cancer Ther., 2017, 16, 871.
[6] Ashman, N., et al. Non-internalising antibody–drug conjugates, Chem. Soc. Rev., 2021, 51, 9182.
[7] Su, D., et al. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol., 2021; 12, 68, 7926.
[8] Lyon R. P., et al. Reducing hydrophobicity of homogeneous antibody‒drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 2015, 33, 733.
[9] Burke, P.J., et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol. Cancer Ther. 2017, 16, 116.
[10] Simmons, J. K., et al. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicology and applied pharmacology, 2020, 392, 114932.
[11] Zhao，R. Y., et al. Synthesis and Evaluation of Hydrophilic Linkers for AntibodyMaytansinoid Conjugates. J. Med. Chem., 2011, 54, 3606.
[12] Kern, J. C., et al. Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody−Drug Conjugates. J. Am. Chem. Soc., 2016, 138, 4, 1430.
[13] Zhang, D., et al. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues, Drug Metabolism and Disposition, 2019, 47, 1146.
[14] Kovtun, Y. V., et al. Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance. Cancer Res., 2010, 70, 2528.